Lilly picks a Foghorn target; Mineralys’ $120M PIPE; Sana’s $165M offering

Plus, news about Telix, QSAM Bio­sciences, Nicox, and Kowa:

Eli Lil­ly se­lects Foghorn can­di­date for de­vel­op­ment: Foghorn’s stock $FHTX jumped 16% on Thurs­day morn­ing af­ter it said the phar­ma gi­ant se­lect­ed its oral BRM se­lec­tive in­hibitor for clin­i­cal de­vel­op­ment. The com­pa­nies plan to test FHD-909 in pa­tients with BRG1 mu­tat­ed non-small cell lung can­cer as part of a deal inked in 2021 that can pro­vide up to $1.3 bil­lion in mile­stones.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.